

# Importance of Transplantation History in ABO Discrepancies

CHRISTINA THOMPSON, MARIANELA NEAL, NICOLE PETERS

**ABBREVIATIONS:** BMT = bone marrow transplantation; PBSCT = peripheral blood stem cell transplantation.

**INDEX TERMS:** ABO and organ transplant; ABO and stem cell transplant; ABO discrepancy.

Clin Lab Sci 2005;18(1):5

*Christina Thompson EdD CLS(NCA) MT(ASCP)SBB is Clinical Laboratory Sciences Program Director, Texas A&M University-Corpus Christi, Corpus Christi TX.*

*Marianela Neal MT(ASCP)SBB is Blood Bank Supervisor, Christus Spohn Shoreline, Corpus Christi TX.*

*Nicole Peters MT(ASCP) works in the Blood Bank, Christus Spohn Shoreline, Corpus Christi TX.*

**Address for correspondence:** Christina Thompson CLS(NCA) MT(ASCP) SBB, Clinical Laboratory Sciences Program, Texas A&M University-Corpus Christi, 6300 Ocean Dr, Corpus Christi TX 78412. (361)-825-2473, (361) 825-3719 (fax). [cthomp@falcon.tamucc.edu](mailto:cthomp@falcon.tamucc.edu)

A complete history is important for the solution of blood bank typing problems and, with the increasing numbers of transplantation procedures, a patient's history may include transplantation at major medical centers with a subsequent return to the local community hospital. If the recipient and donor are different ABO blood types, both stem cell and organ transplantation demonstrate challenging considerations for transfusion support both during and after the procedure. Two cases are presented to demonstrate the importance of a complete history for the solution of ABO typing problems.

*The peer-reviewed Clinical Practice Section seeks to publish case studies, reports, and articles that are immediately useful, are of a practical nature, or contain information that could lead to improvement in the quality of the clinical laboratory's contribution to patient care, including brief reviews of books, computer programs, audiovisual materials, or other materials of interest to readers. Direct all inquiries to Bernadette Rodak MS CLS(NCA), Clin Lab Sci Clinical Practice Editor, Clinical Laboratory Science Program, Indiana University, Fesler 409, 1120 South Avenue, Indianapolis IN 46202-5113. [brodak@iupui.edu](mailto:brodak@iupui.edu).*

## CASE 1

A 53-year-old male with a history of multiple myeloma was admitted to the hospital with shortness of breath and a cough. A request for two units of packed red blood cells was received by the blood bank. A review of the patient's history showed diabetes and a stem cell transplant a year ago. Previous blood bank typing revealed a type B positive with no discrepancies. These records also showed that the patient had several previous admissions and had received transfusions of compatible B positive blood and components without complications. Because of the difference in the current blood type, A positive, and the previous type, the patient was recollected and given a second ID wrist band for confirmation. A recollected sample matched the current results and typed as A positive. Current and historical typing results are included in Table 1.

**Table 1.** Case 1 – current and historical ABO typing

	Anti-A	Anti-B	A cells	B cells
Current sample	3+	Neg	Neg	W+
Historical results	Neg	4+	3+	Neg

## CASE 2

A 57-year-old man was admitted to the hospital unconscious and in septic shock. The patient's blood pressure at admission was 60/0 and laboratory results were: Hgb – 11.8 g/dL, Hct – 0.335 L/L, and WBC 52 x 10<sup>9</sup>/L. Two units of packed red blood cells were ordered to treat the combination of anemia and shock. Blood type results showed an A positive with a mixed field reaction in the Anti-A. The 'mixed field' results with anti-A sera showed one large agglutinate with 'free cells' in the background. Discussion with the family revealed the patient had been admitted to a hospital in another city two weeks prior for a liver transplant. A call to that transfusion service revealed that the patient's original blood type was A positive and he had received an O positive liver. During hospitalization, the patient received 11 units of O positive blood, 14 units of fresh frozen plasma type A or AB, pooled cryoprecipitate, and type O pooled platelets.

## DISCUSSION

Case 1 demonstrates ABO typing problems associated with bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT). Support for ABO mismatched allogeneic transplantations depends on whether the transplantation introduces a novel ABO antigen (major incompatibility), a novel ABO antibody (minor incompatibility), or both a novel ABO antigen and antibody (both major and minor incompatibility). In BMT and PBSCT, transfusion problems can be caused by antibodies present before transplantation or by antibodies developed after transplantation.<sup>1-8</sup> Since recipient derived immunoglobulins present before transplantation may persist for weeks or months, even in the presence of engraftment from the donor, a major incompatibility (novel antigen) may cause a positive direct antiglobulin test (DAT) and allo-immune hemolytic anemia.<sup>2</sup> Tasaki reported the presence of recipient antibody in a patient one year after transplantation.<sup>8</sup> This patient with unexplained hemolysis demonstrated the new blood type and a negative DAT; however, recipient antibody was present in an eluate performed on the red cells.

Red cell transfusion for BMT or PBSCT with major incompatibility (novel antigen) should initially be type O with a change to the donor type when the recipient's original antibodies disappear. If hemolysis is suspected, a DAT and an elution should be performed. The elution should be performed even if the DAT is negative and the eluate tested with A, B, and O cells to demonstrate the presence of ABO antibodies as well as other red cell antibodies.<sup>1-3,8</sup>

Minor ABO mismatched BMT or PBSCT (novel antibody) may be associated with immediate or delayed hemolysis. Immediate hemolysis is a result of donor plasma present in the transplant and delayed hemolysis is the result of donor lymphocyte induced antibody against the recipient's antigens.<sup>3</sup> Delayed hemolysis may be more common in PBSCT than in BMT because more lymphocytes are present in the transplant.<sup>4</sup> As in the case of major incompatibility, if delayed hemolysis is suspected, a DAT and elution should be performed and tested with A, B, and O cells.<sup>1-3,7</sup> A relatively high return of host-type lymphopoiesis and/or host-type hematopoiesis can occur following allogeneic bone marrow transplants and are referred to as "mixed chimeras." Mixed chimeras have a two-cell population—one from the recipient and one from the donor—and demonstrate a mixed cell blood typing reaction. However, these patients don't appear to have other immunohematologic complications.<sup>2</sup>

The patient in Case 1 was originally B positive and, after myeloablation, had received PBSCT from an A positive donor. This case is an example of major and minor incompatibility (novel antigen and novel antibody). Initial red cell transfusions should be type O with a change to the donor type when recipient antibodies disappear. After a year, the patient's blood type had changed to the donor type, A positive. If the patient had any indication of immune hemolysis or the presence of anti-A in the reverse type or eluate, type O cells would be recommended for transfusion. There was no indication of hemolysis in this case. The patient had a negative direct antiglobulin test and elution. In addition, the reverse type demonstrated a weak anti-B with no anti-A. Type A blood was transfused to the patient with no complications.

Case 2 demonstrates problems associated with an ABO mismatched organ transplant. Although ABO identical organs demonstrate the best survival, group O organs are often transplanted to recipients with other ABO types. ABO mismatch with organ transplantation presents different problems than BMT or PBSCT since all incompatibilities are minor incompatibilities involving novel antibodies. Donor lymphocytes in the new organ or in tissue transplanted with the new organ may continue to produce ABO or other allo-antibodies and may cause hemolysis if incompatible with the recipient's red blood cells. These donor lymphocytes and the potential for hemolysis may persist for weeks.<sup>9-11</sup> The frequency and severity of graft antibodies generally increase in patients treated for immunosuppression with cyclosporine only and with the amount of lymphoid content present in the donor organ.<sup>10,11</sup> Because of the potential for hemolysis, type O red blood cells are indicated for transfusion before, during, and immediately after ABO incompatible organ transplant.<sup>1,11</sup> Donor antibodies and hemolysis have been detected over a year after transplantation. Therefore, if hemolysis is suspected, a DAT and eluate should be performed.

In Case 2, the patient had a negative DAT and eluate and there was no indication of hemolysis. However, since the patient had received a liver transplant just two weeks prior to this admission, the possibility still existed that delayed hemolysis could develop due to antibodies produced by donor lymphocytes. The transfusion facility chose to crossmatch and transfuse type O red cells. The patient received two units of packed red blood cells with no complications.

These cases demonstrate the importance of a complete history from patients for resolution of ABO typing problems. Obtaining the history has become more difficult because

patients receive treatment from a variety of specialists and transplantation services and may return to the local community hospital for treatment of complications. The transfusion facility may need to contact previous physicians, medical facilities, or the patient's family, as well as obtain information from current and previous admissions. Although it may be difficult to obtain a complete history, these two cases demonstrate the necessity of complete investigation to solve typing problems and to provide the optimum blood component for transfusion.

REFERENCES

1. Mintz PD, editor. Transfusion therapy: clinical principles and practice. American Association of Blood Banks. 1998.
2. Klumpp TR. Immuno-hematologic complications of bone marrow transplantation. Bone Marrow Transplant 1991;8(3):159-70.
3. Lapierre V, Kuentz M, Tiberghien P. Allogeneic peripheral blood hematopoietic stem cell transplantation: guidelines for red blood cell immuno-hematological assessment and transfusion practice. Bone Marrow Transplant 2000;25:507-12.
4. Laurencet FM, Samii K, Bressoud A, and others. Massive delayed hemolysis following peripheral blood stem cell transplantation with minor ABO incompatibility. Hematol Cell Ther 1997;39(3):159-62.
5. Lopez A, de la Rubia J, Arriaga F, and others. Severe hemolytic anemia due to multiple red cell alloantibodies after an ABO-incompatible allogeneic bone marrow transplant. Transfusion 1998;38(3):247-51.
6. Oziel-Taieb S, Faucher-Barvey C, Chabannon C, and others. Early and fatal immune haemolysis after so-called 'minor' ABO-incompatible peripheral blood stem cell allotransplantation. Bone Marrow Transplant 1997;19(11):1155-6.
7. Tasaki T, Sasaki S, Gotoh K, and others. Multiple red blood cell antibodies produced by donor B lymphocytes after ABO-matched allogeneic bone marrow transplantation. Transfus Sci 1999;20(2):121-7.
8. Tasaki T, Saloh S, Gotoh K, and others. Transfusion-related problems following major ABO-incompatible bone marrow transplantation. Transfus Apheresis Sci 2003;28(2):155-61.
9. Bakr MA, Foda MA, Shokeir AA, and others. Haemolytic anaemia after ABO-mismatched living-donor kidney transplants. Transplant Proc 1993;25:2297-8.
10. Bracey AW. Anti-A of donor lymphocyte origin in three recipients of organs from the same donor. Vox Sang 1987;53(3):181-3.
11. Hunt BJ, Yacoub M, Amin S, and others. Induction of red blood cell destruction by graft-derived antibodies after minor ABO-mismatched heart and lung transplantation. Transplantation 1988;46(2):246-9.



GEICO AUTO INSURANCE. BECAUSE ONE INDUSTRY

**LEADER**

DESERVES ANOTHER.

SPECIAL DISCOUNT  
FOR ASCLS MEMBERS\*



You have plenty of great reasons to be a part of ASCLS. Now GEICO gives you one more: a special member discount on your auto insurance.\*

Call **1-800-368-2734** for your free rate quote today, and be sure to mention your ASCLS affiliation.

GEICO offers you:

- Outstanding, 24-hour service from knowledgeable insurance professionals
- Fast, fair claim handling, with many claims settled within 48 hours
- Guaranteed claim repairs at GEICO-approved facilities\*

Find out just how much you could save – and how much you'll get – with GEICO.

**1-800-368-2734**



\*Discount amount varies in some states. Some discounts, coverages, payment plans, and features are not available in all states or in all GEICO companies. One group discount applicable per policy. Government Employees Insurance Co. • GEICO General Insurance Co. • GEICO Indemnity Co. • GEICO Casualty Co. These companies are subsidiaries of Berkshire Hathaway Inc. GEICO auto insurance is not available in MA or NJ. GEICO, Washington, DC 20076. © 2003 GEICO